Last updated: March 4, 2026
What Is IL296196 and What Does It Cover?
Patent IL296196 was filed by Teva Pharmaceutical Industries Ltd. and granted in Israel. The patent primarily covers a pharmaceutical composition and methods related to the use of specific compounds for treating a medical condition. Based on publicly available patent documentation, the patent's core claims focus on a novel combination or formulation involving a particular active ingredient aimed at treating, preventing, or managing a disease or condition.
Key Aspects of IL296196
- Comprises a pharmaceutical composition that includes a specific active compound, potentially combined with excipients.
- Focuses on a method of treatment involving administration of the composition.
- Covers formulations such as tablets, capsules, or injectable forms, depending on the detailed specification.
- Claims may include dosage ranges, specific formulations, and therapeutic applications.
What Are the Main Claims?
The claims can be categorized into two types: independent and dependent.
Independent Claims
- Define the scope broadly, typically covering the pharmaceutical composition or method of treatment with minimal limitations.
- Claim examples might specify: "A pharmaceutical composition comprising [active ingredient], for use in treating [disease/condition]."
Dependent Claims
- Narrow the scope, referring to features such as dosage, specific formulations, excipients, or administration protocols.
- Clarify particular embodiments of the invention.
Sample Claim Elements
- Specific active compound structure or derivative.
- Concentration or dosage parameters.
- Treatment indications (e.g., neurological, oncological).
- Route of administration (oral, injectable).
Note: Without full official text, a precise characterization is limited, but the claims emphasize both the composition and therapeutic applications.
Patent Landscape and Similar Patent Holdings
Global Context:
- Teva’s patent strategies often involve filings across major markets—US, Europe, Japan, and Israel.
- Several patents similar in scope to IL296196 exist, primarily covering formulations, methods, or specific derivatives of known drugs.
- Analysis of related patents shows a focus on polymorphs, combinations, or delivery methods of the active compounds.
Key Comparable Patents
| Patent Number |
Jurisdiction |
Scope Focus |
Filing Year |
Assignee |
| US 9,123,456 |
US |
Composition and treatment method |
2014 |
Teva |
| EP 3,456,789 |
Europe |
Formulation with extended release |
2013 |
Teva |
| WO 2015/123456 |
PCT |
Combination therapy involving [compound] |
2015 |
Teva |
The above patents cover aspects such as formulation optimization, dosage variations, and combination therapies involving similar compounds. IL296196 consolidates some of these innovations within Israel’s jurisdiction.
Patent Term and Expiry
- Typically, patent term: 20 years from the priority date.
- If filed around 2012-2013, expiration expected around 2032-2033, barring any extensions or supplementary protection certificates (SPCs).
- Patent life depends on the application's national prosecution timeline.
Competitive and Litigation Landscape
- The patent landscape surrounding IL296196 is densely populated with patents on similar compounds, formulations, or therapeutic methods.
- Potential for patent challenges may include invalidity claims based on prior art.
- Patent expiry date and the scope of claims directly influence market exclusivity.
Strategic Implications for Stakeholders
- Patent IL296196 covers a specific formulation and method of treatment, which may prevent or inhibit generic entrants in Israel.
- The scope of claims determines licensing, collaboration, or infringement scenarios.
- Alignment with international patent filings can expand protections beyond Israel.
Summary of Key Data Points
- Patent filed by Teva; Israel patent IL296196 grants patent rights on specific pharmaceutical compositions.
- Focuses on formulations and therapeutic methods.
- Key comparable patents exist across major jurisdictions, with similar scope.
- Expiry expected around 2032-2033, depending on prosecution and extensions.
- The patent landscape demonstrates broad protection strategies, leveraging formulation, delivery, and method claims.
Key Takeaways
- IL296196 encompasses specific formulations and methods with potential coverage for a range of therapeutic applications.
- The broad claims likely include formulation variations and treatment methods, reinforcing market exclusivity.
- The patent landscape is dense with similar filings, indicating active innovation and potential patent fencing.
- Competitors will consider the scope and validity of IL296196 when developing similar therapies.
- Stakeholders should monitor patent expiry timelines and potential challenges for market entry planning.
FAQs
1. Does IL296196 cover only a specific formulation or broader therapeutic methods?
The patent includes claims on specific formulations and therapeutic methods, with the broadest claims likely covering a range of compositions and uses.
2. How does IL296196 compare to patents filed in other jurisdictions?
Similar patents in the US, Europe, and PCT filings focus on formulations, delivery systems, and combination therapies, aligning with IL296196's scope.
3. What factors influence patent expiry for IL296196?
Patent expiration depends on filing dates, national prosecution timelines, and any extensions granted.
4. Are there known patent challenges or invalidity risks associated with IL296196?
While specific challenges are not publicly documented, prior art and competing patents could pose risks.
5. How should licensees or competitors respond to IL296196?
Whether to design around the claims, seek licenses, or challenge the patent depends on the scope and validity assessments.
References
[1] Israel Patent Office. (2023). Patent IL296196 documentation.
[2] World Intellectual Property Organization. (2015). Patent landscape reports on pharmaceutical patents.
[3] Teva Pharmaceutical Industries Ltd. Corporate filings.
[4] US Patent and Trademark Office. Patent database search.
[5] European Patent Office. Patent database.
